[Intermediate doses of cytosine arabinoside in the treatment of acute non-lymphoblastic leukaemia in children]

Med Wieku Rozwoj. 2000;4(1 Suppl 2):33-41.
[Article in Polish]

Abstract

Between 1995-1997, at 7 centres of the Polish Paediatric Leukaemia/Lymphoma Study Group (PPLLSG) treatment was started in 102 children with acute non-lymphoblastic leukaemia. Sixty-two children treated according to the new protocol adjusted for risk factors were evaluated. Thirty-one patients belonged to standard risk and 23 to high risk group. Eight children were not evaluated due to early death. Out of 62 children, 44 (70,9%) achieved remission; in standard and high risk groups the rates of remission were 87,5% and 73%, respectively. Four-year event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS) probability in all patients were: 40,2%, 42% and 59% respectively, in standard risk group: 49,5%, 52,5%, 59,1%; in high risk group: 42%, 43,4% and 57,8%. In comparison with the previous period (1983-1994) EFS increased from 30% to 42%, which was statistically insignificant.

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Antimetabolites, Antineoplastic / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Asparaginase / therapeutic use
  • Child
  • Child, Preschool
  • Cytarabine / administration & dosage*
  • Daunorubicin / therapeutic use
  • Disease-Free Survival
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / mortality
  • Male
  • Poland / epidemiology
  • Prednisone / therapeutic use
  • Remission Induction
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Survival Analysis
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Antimetabolites, Antineoplastic
  • Cytarabine
  • Vincristine
  • Asparaginase
  • Prednisone
  • Daunorubicin

Supplementary concepts

  • PVDA protocol